Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in Marginal Zone Lymphoma
2017-003149-56Phase 2Active
- Sponsor
- University Hospital Ulm
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in marginal zone B-cell lymphoma (MZL) and splenic marginal zone lymphoma (SMZL), sponsored by University Hospital Ulm. Primary endpoint: Complete response rate after induction therapy. Started Jan 2018; status: active.
02
Drugs
obinutuzumab
03
Conditions
marginal zone B-cell lymphoma (MZL)splenic marginal zone lymphoma (SMZL)
Beyond the preview
Go deeper on 2017-003149-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003149-56.